Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors. - sprookjes - yvandenbroek - TriplyDB

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

http://www.wikidata.org/entity/Q37765246

about

mTOR inhibitors in advanced renal cell carcinoma Contemporary Treatment of Metastatic Renal Cell Carcinoma Finding Ponce de Leon's Pill: Challenges in Screening for Anti-Aging Molecules Saudi Oncology Society and Saudi Urology Association combined clinical management guidelines for renal cell carcinoma Recent advances in the management of renal cell carcinoma Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics Chinese guidelines on the management of renal cell carcinoma (2015 edition)Sequence of treatment in locally advanced and metastatic renal cell carcinoma Clinical experience with everolimus in the second-line treatment of advanced renal cell carcinoma Management of inferior vena cava tumor thrombus in locally advanced renal cell carcinoma Rapamycin and its analogues (rapalogs) for Tuberous Sclerosis Complex-associated tumors: a systematic review on non-randomized studies using meta-analysis Multidisciplinary management of clear-cell renal cell carcinoma in Africa and the Middle East: current practice and recommendations for improvement Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma Novel targeting of phosphatidylinositol 3-kinase and mammalian target of rapamycin in renal cell carcinoma Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer Differentiating mTOR inhibitors in renal cell carcinoma Renal tumors: diagnostic and prognostic biomarkers Therapy management of cardiovascular adverse events in the context of targeted therapy for metastatic renal cell carcinoma Targeted therapeutic strategies for the management of renal cell carcinoma γδ T cells for cancer immunotherapy: A systematic review of clinical trials Individualising treatment choices in a crowded treatment algorithm Circulating biomarkers in advanced renal cell carcinoma: clinical applications Evaluating the safety and efficacy of axitinib in the treatment of advanced renal cell carcinoma Everolimus and Malignancy after Solid Organ Transplantation: A Clinical Update Clinical use of cabozantinib in the treatment of advanced kidney cancer: efficacy, safety, and patient selection Multimodality treatment of brain metastases from renal cell carcinoma in the era of targeted therapy Everolimus in the management of metastatic renal cell carcinoma: an evidence-based review of its place in therapy Autophagy in thyroid cancer: present knowledge and future perspectives A comparison of Ku0063794, a dual mTORC1 and mTORC2 inhibitor, and temsirolimus in preclinical renal cell carcinoma models Endothelial Cell mTOR Complex-2 Regulates Sprouting Angiogenesis Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer Renal cell cancer: overview of the current therapeutic landscape.Lenvatinib therapy for the treatment of patients with advanced renal cell carcinoma.Response to post-axitinib treatment in patients with metastatic renal cell carcinoma.The Nephrologist's Tumor: Basic Biology and Management of Renal Cell Carcinoma.A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K Ethical Issues in the Management of Renal Cell Carcinoma.Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.

P2860

Q24612127-F100712F-E0EF-4545-AD82-3EC14841448D Q26740594-81DA5AB3-976C-4768-B59D-C7197D451ADC Q26747742-62640B10-51E7-4CEB-9958-AE025240F686 Q26747767-C15A5C99-925B-4EF7-A4B4-66E02731CCDE Q26750609-474DF6F1-3A07-4A55-B757-26755AE09F1E Q26766240-A6B88F42-05EA-4C78-A5C0-0487951FA58E Q26766292-EBD33055-DF78-47CC-BBF5-B9705803F7ED Q26772206-2FB6C5B0-7E37-41E4-9628-B1318AFA2C31 Q26773653-5879085F-B079-489B-AB6D-913F0BCA5C10 Q26783514-97BA639C-AADC-4DE9-9FBC-12CE1D92CF4A Q26786534-82CC56B4-5AF8-4F78-938D-7F6A611CD5FF Q26799757-FE1585B0-4393-42D7-B295-257FA15E76D0 Q26801279-B4E78E50-F58B-41F9-AC20-3486B16DA3D7 Q26827319-62721AE9-2713-49B5-A56A-39F7FC8C92E6 Q26829730-A4AFAAB6-1973-4BB8-86A1-852C343F5B16 Q26852704-107FC845-E48C-41A7-BB97-21B08FDB9E7D Q26860172-BE922834-95BC-4427-9D62-CC33E620F6A1 Q26860500-F6A5FBCA-9A36-4AD1-B2C1-1AA31C7F1303 Q27013665-6CD9792D-67E5-49F4-9422-A6EADBDFA59A Q27013846-4B89437D-773D-40DA-AD16-998E7C56F8DB Q27021705-D0798C89-4CDC-4AF5-A48A-357BF143B935 Q27023669-C9D99EAE-A792-4C7C-9726-9A274012F4A0 Q27023770-A869EC30-58BB-4B35-9B4A-F25F5AFF0230 Q27028048-DE878AAA-EC28-48CD-91D1-B9D7DFA14BC3 Q28067598-C6703073-C7F5-47D3-BE6B-EA52C5E18412 Q28074834-B48D9C6F-3045-4A72-BCF6-343A9D94FD28 Q28077050-E02E137E-DC01-4597-9E31-DDFFEB877758 Q28079861-08305904-DE0E-49A7-B05E-DB75F3823894 Q28086785-3E83B2BF-4D48-4FFD-AC0D-5196D2E31330 Q28485220-A0AD3CA3-B1A7-489E-B6B6-912A8F07159E Q28547399-09AC235C-4692-4F73-8368-3B02BAE4CEAB Q28554686-8DBEED2E-1678-40AA-83E1-0AE4A6F49C7A Q29620676-5C842997-1B78-4882-BAC9-03A7A95BDEEA Q30248354-DFE2E4B3-7A96-48AF-9B68-EF44ECB4C73E Q30249385-37739F93-3980-4C27-96BB-517A6F19E029 Q30277077-643507DF-DB0C-49C5-A333-3AB6894B056A Q30277177-84AA24D3-E440-4151-9D8A-F0E9B744B6DB Q30301096-B8BA8FD8-A6C9-485C-AC88-ADD95CD5E10C Q30724257-D138EBC2-C53C-463A-9BAC-6ACC3127C626 Q33404258-34ABD76D-B1A6-4904-994B-90D67520A204

P2860

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors.

http://www.wikidata.org/entity/Q37765246

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on September 2010

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Phase 3 trial of everolimus fo ...... nalysis of prognostic factors.

@en

Phase 3 trial of everolimus fo ...... nalysis of prognostic factors.

@nl

type

label

Phase 3 trial of everolimus fo ...... nalysis of prognostic factors.

@en

Phase 3 trial of everolimus fo ...... nalysis of prognostic factors.

@nl

prefLabel

Phase 3 trial of everolimus fo ...... nalysis of prognostic factors.

@en

Phase 3 trial of everolimus fo ...... nalysis of prognostic factors.

@nl

P1433

Q37765246-D31514D5-3662-49DD-BA8B-18D51A82D753

P1476

Q37765246-87B2318A-D2F4-479F-A5C2-319166AF0854

P2093

Q37765246-41C5171B-1B29-4782-A14A-5DE5D8A94273

Q37765246-44F8E276-B15C-4771-AB82-88998840FF92

Q37765246-57400107-1461-4F01-9A16-1B84728B762A

Q37765246-651065D8-3DD3-4E8F-A1BD-FD523021CE7C

Q37765246-6BD08AD7-C4EA-49F0-84DF-2530A0C20259

Q37765246-9AD9F4C9-A3E8-439B-9F69-06BFFAB18F20

Q37765246-A90DADEB-4FB1-44BC-98FC-3DF9F0300B92

Q37765246-B7DEC7B0-0426-4D7A-9351-CAD810D86423

Q37765246-CBF36E78-3F0A-4F86-AE29-2ADD18C420BF

Q37765246-CD2130C6-7B4A-4085-B3EB-021EABFF4F89

P304

Q37765246-168950EB-915E-480B-855B-9FA3CB4F8848

P31

Q37765246-1D5BD784-348A-4FE7-A41F-2219F00C5817

P356

Q37765246-7592235C-AF6A-4488-ABDE-3DC92EB9DCED

P407

Q37765246-85E93ACC-8516-44F3-A4C2-7A76940FCA25

P433

Q37765246-808BBB1C-ABA0-4E44-BE0A-1D94EF5C2812

P478

Q37765246-90E8FA6A-3B3D-49A9-B77B-D73D70BD6493

P50

Q37765246-4D8F4B2C-A16F-41FF-A0EE-FE7F14309630

P577

Q37765246-B0234FB5-DC44-4A2B-BE3D-B4B99D892456

P5875

Q37765246-9F0E5A94-AF5A-495C-955E-01ABC466B5D2

P698

Q37765246-D29E1FB7-CD0D-4C07-837C-9D00B7D3C16A

P921

Q37765246-86B5F13C-774F-4826-B49C-C6882E7A8AFA

P356

P1433

P1476

Phase 3 trial of everolimus fo ...... nalysis of prognostic factors.

@en

P2093

Alain Ravaud

http://www.w3.org/2001/XMLSchema#string

Andrea Kay

http://www.w3.org/2001/XMLSchema#string

Camillo Porta

http://www.w3.org/2001/XMLSchema#string

John A Thompson

http://www.w3.org/2001/XMLSchema#string

Norbert Hollaender

http://www.w3.org/2001/XMLSchema#string

RECORD‐1 Study Group

http://www.w3.org/2001/XMLSchema#string

Robert A Figlin

http://www.w3.org/2001/XMLSchema#string

Robert J Motzer

http://www.w3.org/2001/XMLSchema#string

Sergio Bracarda

http://www.w3.org/2001/XMLSchema#string

Stephane Oudard

http://www.w3.org/2001/XMLSchema#string

P304

4256-4265

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CNCR.25219

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

116

http://www.w3.org/2001/XMLSchema#string

P50

Bernard Escudier

P577

2010-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

44674960

http://www.w3.org/2001/XMLSchema#string

P698

20549832

http://www.w3.org/2001/XMLSchema#string

P921

phase III clinical trial